Mannkind Corp (MNKD)
$1.22
0.00 (0.00%)
MNKD Stock Quote Delayed 15 Minutes
Previous Close
$1.22
Market Cap
177.31M
PE Ratio
-1.01
EPS
-1.21
Volume (Avg. Vol.)
Day's Range
1.22 - 1.22
52-Week Range
0.94 - 2.34
Dividend & Yield
N/A (N/A)
MNKD Stock Predictions, Articles, and Mannkind Corp News
New Development Partnership Could Pay Off Big for MannKind Stock
MannKind scored a collaboration deal with biotechnology giant, United Therapeutics. This development partnership could pay off big.
Why MannKind Stock Is Skyrocketing Today
MannKind (MNKD) stock was flying high on Tuesday following the announcement of a $45-million deal with United Therapeutics (UTHR).
MannKind Stock Is One Step Away From Obliteration
MNKD stock collapsed after disastrously poor Q2 earnings, but the real story is that MannKind now faces a bankruptcy threat.
MannKind Corporation (MNKD) Stock Slides Despite Q2 Revenue Growth
MannKind Corporation (MNKD) stock was sliding after the bell following the company's quarterly earnings report, which included a year-over-year Afrezza revenue growth of 142%.
Don’t Buy MannKind Corporation Stock Under Any Circumstances
With a depressed share price, sales set to double this year, and a traditionally high-growth sector, it can be tempting to view MannKind Corp. (MNKD) as a bargain. Don’t make that mistake.
Is MannKind Corporation Stock Really Worth the Risk?
Volatility has send MannKind stock's options prices through the roof. You could sell option premium here, but is MNDK worth the risk?
Metrics for Earnings Visibility Keep Mannkind (MNKD) a Sell at recent price of $3.8
The Sell recommendation for Mannkind Corp is the outcome of an analytical process that is proprietary which generated conclusions that were above average in 2 areas: an economic sector rated above average in attractiveness, and a mathematical computation of risk/reward that is better than average; and produced below average results in 4 areas: an industry group rated below average in attractiveness, a ranking in the company's sector that is in the middle third, ranking in the company's industry group that is in the middle third-below average, and analytical scoring that is well below average.
Friday’s Vital Data: MannKind Corporation (MNKD), Apple Inc. (AAPL) and Netflix, Inc. (NFLX)
MannKind (MNKD) options soar on Afrezza label win, Apple (AAPL) is plagued by iPhone 8 battery bloating, while Netflix (NFLX) raised prices.
MannKind Corporation (MNKD) Shares Up Despite Earnings Miss
MannKind (MNKD) stock was up on Tuesday despite the company reporting an earnings and revenue miss in its second quarter of 2017.
MannKind Corporation (MNKD) Stock Slammed Despite Smaller Q1 Losses
Just days after announcing a breakthrough distribution pact, MNKD delivered news of smaller first-quarter losses.
MannKind Corporation (MNKD) Shares Continue to Surge on ‘One Drop’ News
MannKind (MNKD) stock is still on the rise following the announcement of its deal with One Drop and speculation of a sale.
MannKind Corporation (MNKD) Stock Sinks on Reverse Stock Split Plans
MannKind Corporation (MNKD) shares are down as the company approved a reverse split that will reduce from 700 million to 140 million shares.
MannKind Corporation (MNKD) Stock Is a Lost Cause After Q3 Earnings
MannKind (MNKD), down 90% over the past couple of years, is still fighting an uphill, un-winnable battle. MNKD stock is nearly out of time.
Thursday’s Vital Data: Apple Inc. (AAPL), Micron Technology, Inc. (MU) and MannKind Corporation (MNKD)
Wall Street yawns at Apple (AAPL) iPhone event, Micron (MU) rides DRAM projections and MannKind (MNKD) options bet big on Mylan (MYL) EpiPen rival.
MannKind Corporation (MNKD) Working to Take on Mylan’s EpiPen
MannKind (MNKD) is in the early stages of developing an inhalable form of epinephrine, which could help it take market share from the injectable version.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
